(14 days)
Not Found
No
The device description and performance studies focus on the chemical composition and stability of a glucose control solution, with no mention of AI or ML technologies.
No
The device is a control solution for in vitro diagnostic use, intended to assess the performance of a blood glucose system, not to treat or prevent disease directly.
No
The device is a glucose control solution, not a diagnostic device itself. It is used to assess the performance of a blood glucose system (a diagnostic device), serving as a quality control measure.
No
The device description clearly states it is a "viscosity-adjusted, aqueous liquid control solution" packaged in "plastic dropper tipped bottles," indicating it is a physical product, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "For in vitro diagnostic use".
Furthermore, the device description and intended use align with the definition of an IVD, as it is a control solution used to assess the performance of a blood glucose monitoring system, which is itself an IVD used for diagnosing and monitoring diabetes.
N/A
Intended Use / Indications for Use
For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the TheraSense FreeStyle Blood Glucose System.
Product codes
75 JJX
Device Description
The Liberty Glucose Control consists of a viscosityadjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals and in the home by people with diabetes mellitus
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Tests were performed to verify specific performance characteristics:
- Stability (Accelerated and Real-time)
- Open Vial
- Microbial Stress Stability
- Test precision
Conclusion: Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
K 060481
2006 MAR 9
-
- 510(k) Summary
MAR 9 2006
- 510(k) Summary
-
Introduction: According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand basis for a the determination of substantial equivalence. Submitter: Liberty Healthcare Group, Inc. 8883 Liberty Lane Port St. Luce, FL 34952 Contact Person: John C. Gormley American Biological Technologies, Inc. 940 Crossroads Blvd Seguin, TX 78155 (830) 372-1391 ex. 210 Establishment Registration Number: 1643621 Device Name: Liberty Glucose Control . Common Name: Single Analyte Control Solution, All Types (Assayed and Unassayed) Quality Control Material (assayed and unassayed). Classification Name: Classification: Class I per 21 CFR 862.1660 Product Code: 75 JJX Panel: Chemistry Predicate Devices: Name: TheraSense FreeStyle Control Manufacturer: TheraSense, Inc. 510(k) No.: K031260 Name: Liberty Glucose Control Manufacturer: Liberty Healthcare Group, Inc. 510(k) No.: K052980
1
- Device Description: The Liberty Glucose Control consists of a viscosityadjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.
- Intended Use: The Liberty Glucose Control is intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of TheraSense FreeStyle Blood Glucose Monitor.
Comparison to Predicate Device:
| Characteristic/
| Aspect | Predicate Device No. 1 | Predicate Device No. 2 | New Product |
|---|---|---|---|
| Name | TheraSense FreeStyle | ||
| Control | Liberty Glucose Control | Liberty Glucose | |
| Control | |||
| 510(k), Date | K031260, 12/19/2003 | K052980 11/30/2005 | |
| Number of | |||
| Levels | 1 | 1 | 1 |
| Analyte | Glucose | Glucose | Glucose |
| Container | Plastic bottle with | ||
| dropper-tip | Plastic bottle with dropper | ||
| tip | Plastic bottle with | ||
| dropper tip | |||
| Fill Volume | 4.0 mL | 3.6 mL | 3.6 mL |
| Color | Red | Red | Red |
| Matrix | Buffered aqueous | ||
| solution of D-Glucose, | |||
| viscosity modifier, | |||
| preservatives, and other | |||
| non-reactive ingredients | Buffered aqueous | ||
| solution of D-Glucose, a | |||
| viscosity modifier, | |||
| preservatives, and other | |||
| non-reactive ingredients | Buffered aqueous | ||
| solution of D-Glucose, a | |||
| viscosity modifier, | |||
| preservatives, and | |||
| other non-reactive | |||
| ingredients | |||
| Indications for | |||
| Use | To use with FreeStyle | ||
| Blood Glucose | |||
| Monitoring System for | |||
| quality control purposes | |||
| to verify that the | |||
| FreeStyle Meter and | |||
| Test Strips are working | |||
| right. | Used to check the | ||
| performance of | |||
| Medisense Blood | |||
| Glucose Systems only. | Used to check the | ||
| performance of | |||
| FreeStyle Blood | |||
| Glucose Systems. | |||
| Target | |||
| Population | Professional and home | ||
| use | Professional and home | ||
| use | Professional and | ||
| home use |
2
Performance Studies: Tests were performed to verify specific performance characteristics:
-
- Stability (Accelerated and Real-time)
-
- Open Vial
-
- Microbial Stress Stability
-
- Test precision
Conclusion: Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.
3
510(k) Premarket Notification: Liberty Glucose Control American Biological Technologies, Inc.
6. Truthful and Accuracy Statement
、
This section contains the Truthful and Accurate Statement.
4
Image /page/4/Picture/11 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its wing and tail. The eagle is positioned to the right of a circular arrangement of text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES USA".
Food and Drug Administratio 2098 Gaither Road Rockville MD 20850
Liberty Healthcare Group, Inc. c/o Mr. John Gromley Vice President Quality Assurance/ Regulatory Affairs American Biological Technologies, Inc. 940 Crossroads Blvd. Seguin, TX 78155
Re: K060481 Trade/Device Name: Liberty Glucose Control Regulation Number: 21 CFR& 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I Product Code: JJX Dated: February 14, 2006 Received: February 23, 2006
Dear Mr. Gromley:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
2006 MAR 9
5
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Alberto Gutz
Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known): K060481
Device Name: Liberty Glucose Control
Indications For Use:
For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the TheraSense FreeStyle Blood Glucose System.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use X (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Carol Benam
Division Sign-Off
Office of In Vitro Dlagnostic Device Evaluation and Safety
Page 1 of ____________________________________________________________________________________________________________________________________________________________________
510(K)